-
Argus: 'Strong' End Markets, Cavium Acquisition Make Marvell Technology A Buy
Wednesday, March 7, 2018 - 2:13pm | 434Marvell Technology Group Ltd. (NASDAQ: MRVL) is in a strong position to show investors top-line growth after several years of sales declines, according to Wall Street's newest bull analyst. The Analyst Argus' Jim Kelleher initiated coverage of Marvell Technology Group's stock with a...
-
Domino's Pizza Gains Another Bull: Argus Upgrades To Buy
Wednesday, March 7, 2018 - 10:39am | 393Domino's Pizza, Inc. (NYSE: DPZ)'s stock was upgraded by Baird Tuesday, and another sell-side firm turned bullish on the pizza chain Wednesday. The Analyst Argus' John Staszak upgraded Domino's Pizza's stock rating from Hold to Buy and set a $260 price target....
-
Argus: Albemarle Has 30% Upside On Strong Lithium Demand
Friday, February 23, 2018 - 10:36am | 376Albemarle Corporation (NYSE: ALB) is likely to benefit from a strong lithium outlook, according to Argus. The Analyst Analyst Mike Jaffe initiated coverage of shares of Albemarle with a Buy rating and a $148 price target, suggesting roughly 30 percent upside from current levels. The...
-
Cognizant Technology Has Momentum For Continued Outperformance, Says Argus' Kelleher
Thursday, February 22, 2018 - 3:52pm | 413Cognizant Technology Solutions Corp (NASDAQ: CTSH) has seen its stock rise 15 percent since the start of 2018 on the heels of a 27-percent jump in 2017, and both figures outperform the computing, information processing and storage peer group. Cognizant's fundamentals imply the potential for...
-
Argus Steps To Sideline On Canadian National, Waits For Revenue Growth Or $70 Level
Friday, February 16, 2018 - 11:44am | 331Canadian National Railway (USA) (NYSE: CNI)'s revenue growth appears challenging over the next several quarters, according to Argus. The Analyst Argus analyst John Eade downgraded shares of Canadian National Railway from Buy to Hold. The Thesis Canadian National, though a well-managed...
-
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
Friday, February 16, 2018 - 10:37am | 360Biogen Inc (NASDAQ: BIIB) tumbled 8 percent Wednesday after announcing a cohort expansion for its aducanumab Alzheimer’s trials — a change certain to delay results. The news, coupled with expected sales declines, has converted one analyst from an advocate to an observer. The Rating...
-
Long-Running Bull Market With 'Compelling' Fundamentals Unlikely To Slip, Says Argus Analyst
Thursday, February 8, 2018 - 12:14pm | 367Market participants were beginning to feel uncomfortable with the extended rally that was ongoing since the end of the bear market in March 2009. When the major market gauges reversed course in late January, it didn't come as a surprise. Despite the recent sell-off, which intensified Feb. 5,...
-
With Obstacles To Growth In Sight, Argus Downgrades Clorox
Thursday, February 8, 2018 - 11:22am | 388Margin pressures and private-label competition could impede growth at Clorox Co (NYSE: CLX), according to Argus. The Analyst Argus analyst John Staszak downgraded shares of Clorox from Buy to Hold. The Thesis Clorox could see weak organic growth despite benefiting from low-cost...
-
Argus: MasterCard Shares Could Appreciate 17%
Friday, February 2, 2018 - 11:39am | 377Mastercard Inc (NYSE: MA) reported 20-percent fourth quarter revenue growth to $3.3 billion and adjusted earnings per share of $1.14 — ahead of the $1.12 consensus estimate — on Thursday. The Analyst Argus analyst Stephen Biggar upgraded MasterCard shares from...
-
Argus On AMD's Earnings: Sustainable Growth Prospects Lead To Upgrade
Thursday, February 1, 2018 - 10:09am | 364Advanced Micro Devices, Inc. (NASDAQ: AMD)'s fourth-quarter earnings report on Tuesday was compelling enough for Argus to turn bullish on the stock. The Analyst Argus' Jim Kelleher upgraded AMD's stock rating from Hold to Buy with an $18 price target. The Thesis AMD's earnings...
-
Argus: Kinder Morgan Has 25% Upside Potential
Monday, January 29, 2018 - 10:34am | 308Energy infrastructure company Kinder Morgan Inc (NYSE: KMI) shares had a lean run for much of 2017, and the stock is down over 15 percent over the past year. The Analyst Argus analyst Bill Selesky upgraded shares of Kinder Morgan from Hold to Buy with a $23 price target. The Thesis Kinder...
-
Argus: Bioverativ Shares Fully Valued After Sanofi Buyout Offer
Wednesday, January 24, 2018 - 12:40pm | 396Bioverativ Inc (NASDAQ: BIVV) agreed to be acquired by Sanofi SA (ADR) (NYSE: SNY) in an $11.6-billion all-cash deal, with the offer price valuing each of Bioverativ shares at $105. The offer price represents a 64-percent premium to Bioverativ's closing price prior to the deal announcement...
-
Amgen Will Make Shareholder-friendly Moves In 2018, Argus Upgrades
Tuesday, January 23, 2018 - 11:22am | 369Amgen, Inc. (NASDAQ: AMGN) is likely to helped by both fundamental catalysts and the positive impact of the new U.S. tax law, an analyst said. The Analyst Argus analyst David Toung upgraded Amgen from Hold to Buy and set a price target of $220. In November, the firm had downgraded Amgen on...
-
Argus Turns Bullish On Abercrombie, Sees Upside To $25
Friday, January 19, 2018 - 10:45am | 383Abercrombie & Fitch Co. (NYSE: ANF) bottomed last year at $8.81, but shares have since rebounded to nearly $20. Despite the more than doubling in value, at least one Wall Street analyst sees further upside ahead on the basis of the retailer's turnaround plan. The Analyst Argus...
-
Competitive Headwinds Could Leave Hawaiian Holdings Grounded; Argus Downgrades
Thursday, January 11, 2018 - 12:53pm | 376Regional airline Hawaiian Holdings, Inc. (NASDAQ: HA) could have its hands full in warding off competitive threats from national carriers, according to Argus. The Analyst Argus analyst John Staszak downgraded shares of Hawaiian Holdings from Buy to Hold. The Thesis The entry of...